Open Access Drug Development Tools Feature in New IMI Call for Proposals

Innovative Medicines InitiativeNew open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of the Call is over EUR 80 million. Half of this comes from the European Commission's Horizon 2020 programme and will fund the participation in the projects of universities, small and medium-sized companies, patient groups etc. The other half comes from large pharmaceutical companies and IMI Associated Partners, who do not receive EU funding through IMI but finance their own participation in our projects.

Open access tools for the genetics of disease - Many diseases have a genetic component, yet we lack the tools to study many of the genes behind diseases. This topic aims to develop a set of open access tools to facilitate the study around 1 000 of the 3 000 genes thought to be implicated in disease and that could be targeted by drugs. The results of the project will be made fully available to the scientific community by open access.

Optimising future obesity treatment - Obesity affects some 650 million people globally, placing them at greater risk of complications such as heart disease, diabetes and cancer to name a few. This topic aims to better understand obesity as a disease by identifying subgroups of people with obesity that will ultimately pave the way for better, more personalised prevention and lifestyle interventions, as well as treatments for obesity and its complications. The project will also focus on diabetes (both types 1 and 2) as examples of conditions that are influenced by obesity in a complex way.

Environmental impacts of medicines - Active ingredients from medicines can get into the environment through a variety of routes, and once there they can prove harmful to wildlife and ecosystems. In the EU, new medicines are required to undergo an environmental risk assessment (ERA). This topic will help to reduce the impact of medicines on the environment in three ways. Firstly, it will deliver tools to identify environmental risks associated with medicines under development. Secondly, it will prioritise which existing medicines (introduced before the ERA) should go through a tailored environmental assessment. Finally, it will create a publicly-available database to make environmental data on human medicinal products more transparent to all stakeholders.

Pierre Meulien, IMI Executive Director commented: "If we want to enjoy the benefits of the genomic revolution, we have to develop tools to study in detail the genes that influence our health. By taking an open access approach, the new topic launched as part of today's Call for proposals will maximise the impacts of its results by making it possible for researchers worldwide to access and use them in their own work."

For more information on IMI2 - Call 17, including the full Call text and details of how to apply, please visit:
http://www.imi.europa.eu/imi2-call-17

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI2 programme, IMI has a budget of €3.3 billion for the period 2014-2020. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

Northern Lincolnshire and Goole NHS Foun…

Northern Lincolnshire and Goole NHS Foundation Trust (NLAG) has launched new NHS App features to transform the way patients access and manage their appointments within the NHS. The programme, known...

Genomics England Deploys Sectra Imaging …

Genomics England has completed installation of an enterprise imaging system that will help to support a world-pioneering initiative for cancer research. The programme is linking whole genome sequencing, pathology and...

Orion Health Strengthens French Business…

Orion Health is strengthening its presence in France with the appointment of digital health industry heavyweight, Tristan Debove, to lead its operations. Tristan Debove has more than 25 years of experience...

AI Approach may Help Detect Alzheimer's …

Although investigators have made strides in detecting signs of Alzheimer's disease using high-quality brain imaging tests collected as part of research studies, a team at Massachusetts General Hospital (MGH) recently...

AI Predicts Cancer Patient Survival by R…

A team of researchers from the University of British Columbia and BC Cancer have developed an artificial intelligence (AI) model that predicts cancer patient survival more accurately and with more...

Virtual Reality Games can be Used as a T…

Virtual reality gamers (VR game) who finished it faster than their fellow gamers also have higher levels of general intelligence and processing capacity. This was the result of a study...

Will Future Computers Run on Human Brain…

A "biocomputer" powered by human brain cells could be developed within our lifetime, according to Johns Hopkins University researchers who expect such technology to exponentially expand the capabilities of modern...

Detecting Anaemia Earlier in Children Us…

Researchers at UCL and University of Ghana have successfully predicted whether children have anaemia using only a set of smartphone images. The study, published in PLOS ONE, brought together researchers and...

AI can Help Optimize CT Scan X-Ray Radia…

Computed tomography (CT) is one of the most powerful and well-established diagnostic tools available to modern medicine. An increasing number of people have been opting for CT scans, raising concerns...

Study Reveals Smartphone Spyware Apps ar…

Smartphone spyware apps that allow people to spy on each other are not only hard to notice and detect, they also will easily leak the sensitive personal information they...

Orion Health Appoints Mark Hindle as Vic…

Orion Health has appointed Mark Hindle as its new vice president for the UK and Ireland. Mark has joined the leading supplier of digital tools to improve healthcare experience from...